Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Allen C Ho

Showing results (131-140 of 245) with videos related to

Pageof 25
Sort By:
Ophthalmology|November 1, 2006
Pars plana vitrectomy versus combined pars plana vitrectomy-scleral buckle for primary repair of pseudophakic retinal detachmentEric D Weichel, Adam Martidis, Mitchell S Fineman, et al.
American Journal of Ophthalmology|September 20, 2015
Optical Coherence Tomography Angiography and En Face Optical Coherence Tomography Features of Paracentral Acute Middle MaculopathyJayanth Sridhar, Abtin Shahlaee, Ehsan Rahimy, et al.
American Journal of Ophthalmology|July 20, 2021
Fluctuations in Central Subfield Thickness Associated With Worse Visual Outcomes in Patients With Diabetic Macular Edema in Clinical Trial SettingMatthew R Starr, Mirataollah Salabati, Raziyeh Mahmoudzadeh, et al.
Ophthalmology Science|November 7, 2022
Factors Associated with Fluctuations in Central Subfield Thickness in Patients with Diabetic Macular Edema Using Diabetic Retinopathy Clinical Research Protocols T and VAva Torjani, Raziyeh Mahmoudzadeh, Mirataollah Salabati, et al.
Ophthalmic Surgery, Lasers & Imaging Retina|May 26, 2021
Characterizing Progression to Neovascular AMD in Fellow Eyes of Patients Treated With Intravitreal Anti-VEGF InjectionsMatthew R Starr, David Xu, Nicholas Boucher, et al.
Ophthalmology|July 13, 2014
Twenty-four-month efficacy and safety of 0.5 mg or 2.0 mg ranibizumab in patients with subfoveal neovascular age-related macular degenerationAllen C Ho, Brandon G Busbee, Carl D Regillo, et al.
Ophthalmology|November 18, 2017
Long-Term Visual Outcomes and Safety Profile of 27-Gauge Pars Plana Vitrectomy for Posterior Segment DiseaseM Ali Khan, Alexander Kuley, Christopher D Riemann, et al.
Seminars in Ophthalmology|September 5, 2015
Alternating Bi-Weekly Intravitreal Ranibizumab and Bevacizumab for Refractory Neovascular Age-Related Macular Degeneration with Pigment Epithelial Detachment<sup></sup>Andre J Witkin, Nadim Rayess, Sunir J Garg, et al.
Ophthalmic Surgery, Lasers & Imaging : the Official Journal of the International Society for Imaging in the Eye|October 12, 2011
Ranibizumab for eyes previously treated with pegaptanib or bevacizumab without clinical responseRichard S Kaiser, Omesh P Gupta, Carl D Regillo, et al.
Retina (Philadelphia, Pa.)|November 28, 2007
Intravitreal bevacizumab (avastin) in central retinal vein occlusionJason Hsu, Richard S Kaiser, Arunan Sivalingam, et al.
Pageof 25

Showing results (131-140 of 245) with videos related to

Sort By:
Pageof 25
Ophthalmology|November 1, 2006
Pars plana vitrectomy versus combined pars plana vitrectomy-scleral buckle for primary repair of pseudophakic retinal detachmentEric D Weichel, Adam Martidis, Mitchell S Fineman, et al.
American Journal of Ophthalmology|September 20, 2015
Optical Coherence Tomography Angiography and En Face Optical Coherence Tomography Features of Paracentral Acute Middle MaculopathyJayanth Sridhar, Abtin Shahlaee, Ehsan Rahimy, et al.
American Journal of Ophthalmology|July 20, 2021
Fluctuations in Central Subfield Thickness Associated With Worse Visual Outcomes in Patients With Diabetic Macular Edema in Clinical Trial SettingMatthew R Starr, Mirataollah Salabati, Raziyeh Mahmoudzadeh, et al.
Ophthalmology Science|November 7, 2022
Factors Associated with Fluctuations in Central Subfield Thickness in Patients with Diabetic Macular Edema Using Diabetic Retinopathy Clinical Research Protocols T and VAva Torjani, Raziyeh Mahmoudzadeh, Mirataollah Salabati, et al.
Ophthalmic Surgery, Lasers & Imaging Retina|May 26, 2021
Characterizing Progression to Neovascular AMD in Fellow Eyes of Patients Treated With Intravitreal Anti-VEGF InjectionsMatthew R Starr, David Xu, Nicholas Boucher, et al.
Ophthalmology|July 13, 2014
Twenty-four-month efficacy and safety of 0.5 mg or 2.0 mg ranibizumab in patients with subfoveal neovascular age-related macular degenerationAllen C Ho, Brandon G Busbee, Carl D Regillo, et al.
Ophthalmology|November 18, 2017
Long-Term Visual Outcomes and Safety Profile of 27-Gauge Pars Plana Vitrectomy for Posterior Segment DiseaseM Ali Khan, Alexander Kuley, Christopher D Riemann, et al.
Seminars in Ophthalmology|September 5, 2015
Alternating Bi-Weekly Intravitreal Ranibizumab and Bevacizumab for Refractory Neovascular Age-Related Macular Degeneration with Pigment Epithelial Detachment<sup></sup>Andre J Witkin, Nadim Rayess, Sunir J Garg, et al.
Ophthalmic Surgery, Lasers & Imaging : the Official Journal of the International Society for Imaging in the Eye|October 12, 2011
Ranibizumab for eyes previously treated with pegaptanib or bevacizumab without clinical responseRichard S Kaiser, Omesh P Gupta, Carl D Regillo, et al.
Retina (Philadelphia, Pa.)|November 28, 2007
Intravitreal bevacizumab (avastin) in central retinal vein occlusionJason Hsu, Richard S Kaiser, Arunan Sivalingam, et al.
Pageof 25